Clinical Trial

Specifying the Anti-inflammatory Effects of Ziltivekimab

Study acronym: SPIDER
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-07
notable Primary completion pushed: 2026-07-01 -> 2026-09-04 2026-08-07
Trial Details
NCT Number NCT06263244
Lead Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions Atherosclerosis, Inflammation
Enrollment 40 participants
Start Date 2024-05-03
Primary Completion 2026-09-04 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-06